Cargando…

Prognostic value of nuclear morphometry in myxoid liposarcoma

Myxoid liposarcoma (MLS) accounts for 20%‐30% of liposarcoma and the round cell component (RCC) is believed to be a specific poor prognostic factor. However, the RCC assessment criteria are vaguely defined and, therefore, are inconsistently employed by pathologists. In this study, we modified and ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawaguchi, Kengo, Kohashi, Kenichi, Iwasaki, Takeshi, Yamamoto, Takeo, Ishihara, Shin, Toda, Yu, Yamamoto, Hidetaka, Nakashima, Yasuharu, Oda, Yoshinao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154898/
https://www.ncbi.nlm.nih.gov/pubmed/36661410
http://dx.doi.org/10.1111/cas.15729
_version_ 1785036223730941952
author Kawaguchi, Kengo
Kohashi, Kenichi
Iwasaki, Takeshi
Yamamoto, Takeo
Ishihara, Shin
Toda, Yu
Yamamoto, Hidetaka
Nakashima, Yasuharu
Oda, Yoshinao
author_facet Kawaguchi, Kengo
Kohashi, Kenichi
Iwasaki, Takeshi
Yamamoto, Takeo
Ishihara, Shin
Toda, Yu
Yamamoto, Hidetaka
Nakashima, Yasuharu
Oda, Yoshinao
author_sort Kawaguchi, Kengo
collection PubMed
description Myxoid liposarcoma (MLS) accounts for 20%‐30% of liposarcoma and the round cell component (RCC) is believed to be a specific poor prognostic factor. However, the RCC assessment criteria are vaguely defined and, therefore, are inconsistently employed by pathologists. In this study, we modified and applied two established grading systems to evaluate nuclear atypia (namely, the World Health Organization/International Society of Urological Pathology and the Fuhrman grading in renal cell carcinoma) in 64 MLS cases. Detailed software‐based assessments of the morphology and the cellularity were performed. DNA mutation analysis, comprehensive mRNA expression analysis, and immunohistochemistry were also performed. Our findings revealed that the high–nuclear‐grade group according to the modified Fuhrman grading system exhibited a significantly poor disease‐free survival (hazard ratio: 4.43; 95% confidence interval: 0.9‐22.6; p = 0.047). On the other hand, the cellularity was significantly higher in the modified Fuhrman high‐grade group (p = 0.010 at the percentage of the hypercellular area; p = 0.003 at the maximum cell density) but did not qualify per se as a poor prognostic factor in the survival analyses. Furthermore, the modified Fuhrman high‐grade group significantly expressed the cell cycle–related genes (such as FOXM1, PLK1, and CDK1). In conclusion, our analyses suggest that an evaluation focusing on nuclear morphology (rather than on cellular density) can be more reliable in predicting the MLS prognosis.
format Online
Article
Text
id pubmed-10154898
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101548982023-05-04 Prognostic value of nuclear morphometry in myxoid liposarcoma Kawaguchi, Kengo Kohashi, Kenichi Iwasaki, Takeshi Yamamoto, Takeo Ishihara, Shin Toda, Yu Yamamoto, Hidetaka Nakashima, Yasuharu Oda, Yoshinao Cancer Sci Original Articles Myxoid liposarcoma (MLS) accounts for 20%‐30% of liposarcoma and the round cell component (RCC) is believed to be a specific poor prognostic factor. However, the RCC assessment criteria are vaguely defined and, therefore, are inconsistently employed by pathologists. In this study, we modified and applied two established grading systems to evaluate nuclear atypia (namely, the World Health Organization/International Society of Urological Pathology and the Fuhrman grading in renal cell carcinoma) in 64 MLS cases. Detailed software‐based assessments of the morphology and the cellularity were performed. DNA mutation analysis, comprehensive mRNA expression analysis, and immunohistochemistry were also performed. Our findings revealed that the high–nuclear‐grade group according to the modified Fuhrman grading system exhibited a significantly poor disease‐free survival (hazard ratio: 4.43; 95% confidence interval: 0.9‐22.6; p = 0.047). On the other hand, the cellularity was significantly higher in the modified Fuhrman high‐grade group (p = 0.010 at the percentage of the hypercellular area; p = 0.003 at the maximum cell density) but did not qualify per se as a poor prognostic factor in the survival analyses. Furthermore, the modified Fuhrman high‐grade group significantly expressed the cell cycle–related genes (such as FOXM1, PLK1, and CDK1). In conclusion, our analyses suggest that an evaluation focusing on nuclear morphology (rather than on cellular density) can be more reliable in predicting the MLS prognosis. John Wiley and Sons Inc. 2023-02-09 /pmc/articles/PMC10154898/ /pubmed/36661410 http://dx.doi.org/10.1111/cas.15729 Text en © 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Kawaguchi, Kengo
Kohashi, Kenichi
Iwasaki, Takeshi
Yamamoto, Takeo
Ishihara, Shin
Toda, Yu
Yamamoto, Hidetaka
Nakashima, Yasuharu
Oda, Yoshinao
Prognostic value of nuclear morphometry in myxoid liposarcoma
title Prognostic value of nuclear morphometry in myxoid liposarcoma
title_full Prognostic value of nuclear morphometry in myxoid liposarcoma
title_fullStr Prognostic value of nuclear morphometry in myxoid liposarcoma
title_full_unstemmed Prognostic value of nuclear morphometry in myxoid liposarcoma
title_short Prognostic value of nuclear morphometry in myxoid liposarcoma
title_sort prognostic value of nuclear morphometry in myxoid liposarcoma
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154898/
https://www.ncbi.nlm.nih.gov/pubmed/36661410
http://dx.doi.org/10.1111/cas.15729
work_keys_str_mv AT kawaguchikengo prognosticvalueofnuclearmorphometryinmyxoidliposarcoma
AT kohashikenichi prognosticvalueofnuclearmorphometryinmyxoidliposarcoma
AT iwasakitakeshi prognosticvalueofnuclearmorphometryinmyxoidliposarcoma
AT yamamototakeo prognosticvalueofnuclearmorphometryinmyxoidliposarcoma
AT ishiharashin prognosticvalueofnuclearmorphometryinmyxoidliposarcoma
AT todayu prognosticvalueofnuclearmorphometryinmyxoidliposarcoma
AT yamamotohidetaka prognosticvalueofnuclearmorphometryinmyxoidliposarcoma
AT nakashimayasuharu prognosticvalueofnuclearmorphometryinmyxoidliposarcoma
AT odayoshinao prognosticvalueofnuclearmorphometryinmyxoidliposarcoma